Skip to main content

Table 4 Immune reconstitution within 1 year post-transplantation (absolute value)

From: Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

  

CD3+

CD3+CD4+

CD3+CD8+

CD19+

CD3-CD56+

Months after allo-HSCT

 

Mean absolute value (109/L, range)

Mean absolute value (109/L, range)

Mean absolute value (109/L, range)

Mean absolute value (109/L, range)

Mean absolute value (109/L, range)

1st(N=202)

Sorafenib group

0.450 (0.025–1.218)

0.086 (0.0070.239)

0.296 (0.0090.938)

0.009 (0.0000.049)

0.137 (0.0240.336)

Control group

0.621 (0.0471.515)

0.085 (0.0070.144)

0.451 (0.0321.392)

0.010 (0.0010.035)

0.193 (0.0790.378)

P

0.267

0.966

0.262

0.870

0.159

3rd(N=188)

Sorafenib group

0.985 (0.1912.835)

0.182 (0.0300.470)

0.681 (0.0772.446)

0.059 (0.0000.336)

0.323 (0.0260.910)

Control group

1.294 (0.5103.779)

0.209 (0.0570.485)

0.977 (0.1833.285)

0.039 (0.0000.102)

0.275 (0.1020.534)

P

0.261

0.501

0.244

0.416

0.519

6th(N=165)

Sorafenib group

1.273 (0.3982.823)

0.257 (0.1050.674)

0.863 (0.2022.633)

0.082 (0.0020.307)

0.272 (0.0950.595)

Control group

1.228 (0.3222.925)

0.232 (0.1050.347)

0.907 (0.1222.500)

0.076 (0.0070.226)

0.246 (0.0980.529)

P

0.858

0.824

0.587

0.557

0.842

9th(N=152)

Sorafenib group

1.394 (0.2113.714)

0.211 (0.0580.458)

1.075 (0.1153.486)

0.111 (0.0010.344)

0.281 (0.0251.069)

Control group

1.236 (0.3563.702)

0.234 (0.0550.546)

0.899 (0.2093.159)

0.137 (0.0020.478)

0.309 (0.0520.903)

P

0.542

0.575

0.469

0.442

0.747

12th(N=141)

Sorafenib group

1.626 (0.3093.906)

0.293 (0.0660.743)

1.220 (0.2223.630)

0.184 (0.0020.558)

0.271 (0.0100.755)

Control group

1.448 (0.5362.735)

0.315 (0.1020.764)

1.025 (0.3332.494)

0.229 (0.0031.208)

0.370 (0.0581.075)

P

0.459

0.627

0.410

0.448

0.141